Biotech Co.* |
Pharma Co. |
Product | Terms/Details (Date) |
Acorda |
Cardinal Health |
Two-year deal to expand the sales force for Acorda's Zanaflex Capsules |
Cardinal will provide about 160 contract sales representatives to address the primary care market (11/10) |
BioDelivery |
Aveva Drug Delivery Systems Inc. |
Aveva will prepare supplies for Phase III trials and commercial manufacturing of BDSI's BEMA Fentanyl |
The product is an oral adhesive disc formulation of the narcotic fentanyl; Aveva will exclusively manufacture and supply the discs (11/8) |
Bioxel Pharma |
Undisclosed European manufacturer |
Renewable two-year deal under which Bioxel will manufacture and supply paclitaxel |
Paclitaxel deliveries to the generic manufacturer are expected to generate sales of $1.5M to $2M per year for Bioxel (10/27) |
Cellegy |
New Harbor Corp. |
New Harbor got rights in China to a nitric oxide donor product for treating anal disorders |
NHC will work through PUMC Pharmaceuticals Co. Ltd. to bring products to market in China; Cellegy would get royalties on sales (11/22) |
Cubist |
ACS Dobfar SpA (Italy) |
ACS was named the single- source supplier of the active ingredient for Cubist's antibiotic drug Cubicin |
ACS has been supplying the ingredient for clinical trials since 1998; it now will be the only supplier (11/30) |
GenTel |
Abnova Corp. (Taiwan) |
Deal to combine technologies to develop multiplex immunoassays |
Terms of the deal were not disclosed (11/9) |
Microbia Inc.* |
Ranbaxy Laboratories Ltd. (India) |
Deal to improve the bio-manufacturing process for a Ranbaxy product |
Microbia is entitled to R&D funding and potential development milestone payments (11/1) |
ProBioGen AG* |
SAFC Biosciences (unit of Sigma-Aldrich Group) |
Deal under which SAFC will market ProBioGen's cell line engineering services |
The services cover development of high-titer cells for production of biotherapeutics; terms were not disclosed (11/1) |
RxKinetix Inc.* |
Indian Immunologicals Ltd. (India) |
RxKinetix will work to develop improved formulations of a hepatitis B vaccine |
The vaccine will be formulated in RxKinetix's ProJuvant delivery platform; terms of the deal were not disclosed (11/2) |
SciGen Ltd. |
Bioton (Poland) and Hefei Life Science & Technolology Investments and Development (China) |
They established a joint venture to manufacture biopharmaceuticals in China |
Among the drugs to be produced there will be SciGen's insulin and hepatitis B products; Hefei has a deal with SciGen to distribute SciGen products in China (12/13) |
TolerRx Inc.* |
Abbott Laboratories |
Deal under which Abbott will manufacture TolerRx's TRX4 monoclonal antibody |
Abbott will supply the product for clinical trials and potential commercial launch; terms were not disclosed (11/29) |
Viragen Inc. |
Kuhnil Pharm Co. Ltd. (South Korea) |
Kuhnil got rights to distribute Multiferon in South Korea |
Viragen gets an up-front fee; Kuhnil gets exclusive rights for 10 years; further terms were not disclosed (12/6) |
ViroPharma |
Eli Lilly and Co. |
Amended manufacturing deal calls for Lilly to increase its supply of Vancocin |
ViroPharma, expecting a possible increase in demand for the Clostridium difficile infection product, will pay Lilly up to $4.5M more than provided for in the original contract through early 2006 (11/3) |
Notes: | |||
# The information in the chart does not cover agricultural agreements or those between biotech companies. | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
ASX = Australian Stock Exchange; AMEX = American Stock Exchange; CDNX = Canadian Venture Exchange. | |||
To read more on related topics, click on one of the words below.